Savant Capital LLC Purchases 153,427 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

Savant Capital LLC lifted its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 134.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 267,776 shares of the biotechnology company’s stock after buying an additional 153,427 shares during the period. Savant Capital LLC owned about 0.17% of Ironwood Pharmaceuticals worth $192,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. McAdam LLC bought a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $40,000. OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $57,000. R Squared Ltd lifted its position in shares of Ironwood Pharmaceuticals by 286.5% in the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 28,735 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its holdings in Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 29,409 shares during the last quarter.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $3.17 on Friday. The company has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $1.18. Ironwood Pharmaceuticals, Inc. has a one year low of $0.53 and a one year high of $5.13. The stock has a market cap of $514.92 million, a P/E ratio of -63.39 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The company had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday. Wells Fargo & Company increased their price objective on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.34.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.